13.05.2024 07:39:16 - dpa-AFX: *REGENERON: FDA ACCEPTS FOR PRIORITY REVIEW SBLA FOR DUPIXENT FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
|
Name |
WKN |
Börse |
Kurs |
Datum/Zeit |
Diff. |
Diff. % |
Geld |
Brief |
Erster |
Schluss |
|
SANOFI SA INHABER EO 2 |
920657 |
Frankfurt |
87,250 |
17.06.24 19:28:41 |
+0,550 |
+0,63% |
87,640 |
87,750 |
86,300 |
87,250 |
|
REGENERON PHARMAC.DL-,001 |
881535 |
Frankfurt |
975,800 |
17.06.24 19:14:09 |
+23,000 |
+2,41% |
973,400 |
979,400 |
967,800 |
975,800 |